Nrg Lu-007: The Raptor Trial For Extensive Stage Small Cell Lung Cancer; Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy For Es-Sclc
Posted Date: Sep 28, 2020
- Investigator: Emily Daugherty
- Specialties: Cancer, Lung Cancer, Oncology, Radiation Oncology
- Type of Study: Device
This trial will be testing if adding radiation to the immunotherapy drug atezolizumab for patients with extensive stage small cell lung cancer (ES-SCLC) can improve progression-free survival (phase II) and overall survival (phase III) when compared to atezolizumab alone.
Criteria:
Patients With Extensive Stage Small Cell Lung Cancer Who Have Recieved 4-6 Cycles Of Etoposide/Platinum Chemotherapy + Atezolizumab Who Have A Stable Or Or Partial Response
Keywords:
Small Cell Lung Cancer, Radiation Therapy, Immunotherapy
For More Information:
Dr. Emily Daugherty, Md
513-584-4073
cancer@uchealth.com